The accelerated approval of Belinostat by the FDA on July 3, 2014 is exciting news for the medical and pharmaceutical communities. Known as the brand name Beleodaq, which is marketed by Topotarget, Belinostat is expected to be available for patients by the end of July 2014. As a formidable treatment for unresectable or relapsed peripheral[…]
Belinostat Early Approval for Lymphoma is Welcomed By Many
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News, FDA Approved 2014 Jul 03, 2014
Canagliflozin FDA Approved For Type 2 Diabetes
Anti-Diabetic, FDA Approval News, FDA Approved 2013 Tags: canagliflozintype 2 Diabetes Mar 29, 2013
Canagliflozin FDA approved as a new and unique treatment for type 2 diabetes. There were nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed positive results with greater glycemic control in patients. The recommended use for Canagliflozin patients includes a strict regimen of diet and exercise. The drug also outperforms similar[…]
Adalimumab FDA Approved For Moderate to Severe Ulcerative Colitis
FDA Approval News, FDA Approved 2012, Monoclonal Antibodies / mAb Tags: 331731-18-1AdalimumabHumira Sep 28, 2012
On Friday (09-28-12) the FDA announced Adalimumab CAS# 331731-18-1 has been approved to treat moderate to severe ulcerative colitis, for those who are unresponsive to corticosteroids or immunosuppressants. News of the approval comes as the FDA cites the two clinical trials with positive outcomes, involving 908 ulcerative colitis patients. “Results from both studies showed 16.5%[…]
FDA Approves Bosutinib for Chronic Myelogenous Leukemia
Chemotherapeutic / Anti-Neoplastic, FDA Approval News Tags: Drug Administrationimatinibleukemia Sep 05, 2012
The U.S. Food and Drug Administration today approved Bosutinib CAS# 380843-75-4, marketed under the trade name Bosulif, to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. An estimated 5,430 men and women will be diagnosed with CML in 2012. Most people with CML have a genetic mutation,[…]
Aflibercept Approved for Colorectal Cancer Treatment
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News Tags: Afliberceptcolorectal cancerIrinotecan Aug 03, 2012
On August 3, 2012, the United States Food and Drug Administration (USFDA) approved ziv-aflibercept injection ( Zaltrap, made by Sanofi and Regeneron Pharmaceuticals, Inc.) for use in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following treatment with an[…]
FDA Approves Everolimus for Advanced Breast Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News, Immunosuppressant Tags: 159351-69-6breast cancerEverolimusmetastatic breast cancerPfizer Jul 20, 2012
Novartis gains FDA approval for Afinitor in advanced breast cancer marking a significant milestone for women battling this disease. Everolimus CAS# 159351-69-6, is the active ingredient for Afinitor®. Click for more information on, and availability of Everolimus. Also, click for more articles on breast cancer and the HER2 receptor. The approval was based on a[…]
New Drugs and Therapies at the Forefront of treatment for Acute Lymphoblastic Leukemia
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic, FDA Approval News, Immunosuppressant Tags: acute lymphoblastic leukemiaHerceptinimatinibleukemiaMethotrexateTrastuzumab Mar 30, 2012
J.R.Stokes Illustrations: Natural Killer: T-cell vs. Leukemia Researchers received encouraging news on March 22, 2012, with the information that the novel drug to treat acute lymphoblastic leukemia, known as Marqibo won an FDA panel vote. The group of oncology advisers voted 7-4 endorsing the Vincristine Sulfate CAS# 2068-78-2 liposomal injection, also known as the brand[…]
